文献速递血栓与止血

儿童免疫性血小板减少症临床病程的生物学分层

Biological stratification of clinical disease courses in childhood immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2021-03-18

本研究纳入147例小于7岁新诊断免疫性血小板减少症(ITP)患儿,随机分为静脉注射免疫球蛋白(IVIg)组或观察组,利用46项临床、基因、免疫表型及血小板自身抗体变量构建生物学风险评分。该评分预测IVIg无持续应答的敏感度为0.91(95%CI 0.80-1.00)、特异度为0.67(95%CI 0.53-0.80),并与观察组1年随访恢复相关。

要点

  • 生物学风险评分可预测IVIg后无持续应答,敏感度0.91、特异度0.67
  • 评分包含血红蛋白、血小板计数、FcγR IIc基因多态性、IgG抗血小板抗体及前期疫苗接种
  • 生物学评分加入预设临床评分可进一步改善对良好ITP病程的区分

核心结论

  • 联合临床与生物学分层可改善对儿童ITP病程及IVIg治疗反应的预测。

研究设计与样本

  • 多中心随机对照研究二次分析,纳入147例小于7岁新诊断ITP患儿,随机分IVIg组或观察组,评估46项变量。

主要发现

  • IVIg组80例中48例(60%)达完全持续应答(血小板≥100×109/L持续至少1个月),32例无应答或仅暂时应答。
  • 生物学风险评分预测无持续应答的敏感度为0.91(95%CI 0.80-1.00),特异度为0.67(95%CI 0.53-0.80)。
  • 观察组67例中该评分亦与1年随访期间的恢复相关。
  • 生物学评分加入预设临床评分后进一步改善了对良好ITP病程的区分。

关键数值与推荐

  • 生物学风险评分入选5个变量:血红蛋白、血小板计数、FcγR IIc基因多态性、IgG抗血小板抗体存在、前期疫苗接种。
  • 完全持续应答定义为血小板≥100×109/L且持续至少1个月。

临床怎么用

  • 对小于7岁新诊断ITP患儿可结合临床与生物学评分预判IVIg应答及病程,辅助治疗决策。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In childhood immune thrombocytopenia (ITP), an autoimmune bleeding disorder, there is a need for better prediction of individual disease courses and treatment outcomes. OBJECTIVE: To predict the response to intravenous immunoglobulins (IVIg) and ITP disease course using genetic and immune markers. METHODS: Children aged younger than 7 years with newly diagnosed ITP (N = 147) from the Treatment With or Without IVIG for Kids with ITP study were included, which randomized children to an IVIg or observation group. A total of 46 variables were available: clinical characteristics, targeted genotyping, lymphocyte immune phenotyping, and platelet autoantibodies. RESULTS: In the treatment arm, 48/80 children (60%) showed a complete response (platelets ≥100 × 109 /L) that lasted for at least 1 month (complete sustained response [CSR]) and 32 exhibited no or a temporary response (absence of a sustained response [ASR]). For a biological risk score, five variables were selected by regularized logistic regression that predicted ASR vs CSR: (1) hemoglobin; (2) platelet count; (3) genetic polymorphisms of Fc-receptor (FcγR) IIc; (4) the presence of immunoglobulin G (IgG) anti-platelet antibodies; and (5) preceding vaccination. The ASR sensitivity was 0.91 (95% confidence interval, 0.80-1.00) and specificity was 0.67 (95% confidence interval, 0.53-0.80). In the 67 patients of the observation arm, this biological score was also associated with recovery during 1 year of follow-up. The addition of the biological score to a predefined clinical score further improved the discrimination of favorable ITP disease courses. CONCLUSIONS: The prediction of disease courses and IVIg treatment responses in ITP is improved by using both clinical and biological stratification.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Schmidt DE, Heitink-Pollé KMJ, Mertens B, et al. Biological stratification of clinical disease courses in childhood immune thrombocytopenia. J Thromb Haemost. 2021. PMID: 33386662. doi:10.1111/jth.15232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。